Please Wait
Applying Filters...
menu
    • menu
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    HealthTech BioActives, leading globally in Flavonoids and Vitamin B12 Derivatives.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Menu

    Zidesamtinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nuvalent's ARROS-1 Data on Zidesamtinib for ROS1-positive NSCLC
    Nuvalent's ARROS-1 Data on Zidesamtinib for ROS1-positive NSCLC

    13 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvalent-to-present-pivotal-data-from-arros-1-clinical-trial-of-zidesamtinib-for-tki-pre-treated-patients-with-advanced-ros1-positive-nsclc-at-wclc-2025-presidential-symposium-302529250.html

    PR NEWSWIRE
    13 Aug 2025
    Share Share
    Nuvalent Publishes Study on Zidesamtinib as ROS1 Inhibitor
    Nuvalent Publishes Study on Zidesamtinib as ROS1 Inhibitor

    29 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvalent-announces-publication-in-molecular-cancer-therapeutics-reinforcing-rational-molecular-design-of-zidesamtinib-as-a-novel-ros1-selective-inhibitor-302441619.html

    PR NEWSWIRE
    29 Apr 2025
    Share Share
    Nuvalent Shares Updated Data On ALK And ROS1 Inhibitors
    Nuvalent Shares Updated Data On ALK And ROS1 Inhibitors

    09 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/updated-data-for-nuvalents-alk-selective-inhibitor-nvl-655-and-ros1-selective-inhibitor-zidesamtinib-continue-to-support-potential-best-in-class-profiles-302241297.html

    PR NEWSWIRE
    09 Sep 2024
    Share Share
    Nuvalent To Present ROS1 And ALK Inhibitor Data At ESMO 2024
    Nuvalent To Present ROS1 And ALK Inhibitor Data At ESMO 2024

    16 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvalent-to-present-updated-data-for-ros1-selective-inhibitor-zidesamtinib-and-alk-selective-inhibitor-nvl-655-at-the-esmo-congress-2024-302197499.html

    PR NEWSWIRE
    16 Jul 2024
    Share Share
    Nuvalent Presents New Preclinical Data of Zidesamtinib at AACR
    Nuvalent Presents New Preclinical Data of Zidesamtinib at AACR

    08 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvalent-presents-new-preclinical-data-supporting-profiles-of-her2-selective-inhibitor-nvl-330-and-ros1-selective-inhibitor-zidesamtinib-at-aacr-annual-meeting-2024-302110869.html

    PR NEWSWIRE
    08 Apr 2024
    Share Share
    Nuvalent to Present New Preclinical Data on NVL-330, and zidesamtinib
    Nuvalent to Present New Preclinical Data on NVL-330, and zidesamtinib

    05 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvalent-to-present-new-preclinical-data-on-her2-selective-inhibitor-nvl-330-and-ros1-selective-inhibitor-zidesamtinib-at-aacr-annual-meeting-2024-302080625.html

    PR NEWSWIRE
    05 Mar 2024
    Share Share